^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | icovamenib (BMF-219) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P-107 Anti-tumor activity of covalent menin inhibitor, BMF-219, in high-grade B-cell lymphoma and multiple myeloma preclinical models
Published date:
08/10/2022
Excerpt:
MM cell lines harboring mutations in TP53, KRAS and NRAS were all sensitive to BMF-219 with growth inhibiton IC50 values in the range of 0.25 μM to 0.5 μM and achieved 100% inhibition at 1 μM...our data demonstrate the novel and robust anti-tumor activity of BMF-219 in HGBCL and MM preclinical models...
